Cite
Utilization of 18 F-Fluorodeoxyglucose-Positron Emission Tomography To Understand the Mechanism of Nicotinamide Phosphoribosyltransferase Inhibitors In Vivo.
MLA
Mudd, Sarah R., et al. “Utilization of 18 F-Fluorodeoxyglucose-Positron Emission Tomography To Understand the Mechanism of Nicotinamide Phosphoribosyltransferase Inhibitors In Vivo.” The Journal of Pharmacology and Experimental Therapeutics, vol. 371, no. 3, Dec. 2019, pp. 583–89. EBSCOhost, https://doi.org/10.1124/jpet.119.259135.
APA
Mudd, S. R., Voorbach, M. J., Cheng, D., Cheng, M., Guo, J., Gao, W., Buchanan, F. G., Tse, C., & Wilsbacher, J. (2019). Utilization of 18 F-Fluorodeoxyglucose-Positron Emission Tomography To Understand the Mechanism of Nicotinamide Phosphoribosyltransferase Inhibitors In Vivo. The Journal of Pharmacology and Experimental Therapeutics, 371(3), 583–589. https://doi.org/10.1124/jpet.119.259135
Chicago
Mudd, Sarah R, Martin J Voorbach, Dong Cheng, Min Cheng, Jun Guo, Wenqing Gao, Fritz G Buchanan, Chris Tse, and Julie Wilsbacher. 2019. “Utilization of 18 F-Fluorodeoxyglucose-Positron Emission Tomography To Understand the Mechanism of Nicotinamide Phosphoribosyltransferase Inhibitors In Vivo.” The Journal of Pharmacology and Experimental Therapeutics 371 (3): 583–89. doi:10.1124/jpet.119.259135.